Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)
NCT ID: NCT01047267
Last Updated: 2012-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2010-06-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimal Dosage of Caspofungin in Critically Ill Patients
NCT01994096
Pharmacokinetics of Micafungin in Critically Ill Patients
NCT01716988
Screening Anti-Fungal Exposure in Intensive Care Units
NCT03136926
Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients
NCT02666716
Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
NCT01533558
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For the investigation of the correlation of the pharmacokinetics of anidulafungin and the disease severity a full pharmacokinetic profile will be obtained. Predictive scoring systems will be used to assess disease severity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 18 years of age
* invasive candidiasis
* admitted to an intensive care unit
Exclusion Criteria
* contra-indication stated in SPC
* neutropenia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JWC Alffenaar
PharmD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JWC Alffenaar, PharmD, PhD
Role: STUDY_CHAIR
University Medical Center Groningen
MJP van Wanrooy, PharmD
Role: PRINCIPAL_INVESTIGATOR
University Medical Center Groningen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
van Wanrooy MJ, Proost JH, Rodgers MG, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW. Limited-sampling strategies for anidulafungin in critically ill patients. Antimicrob Agents Chemother. 2015 Feb;59(2):1177-81. doi: 10.1128/AAC.03375-14. Epub 2014 Dec 8.
van Wanrooy MJ, Rodgers MG, Uges DR, Arends JP, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JW. Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother. 2014;58(1):304-8. doi: 10.1128/AAC.01607-13. Epub 2013 Oct 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANIDULA-133
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.